🌅 Pre-Market Pulse

S&P Futures 7,474.50 ▼ -13.75 (-0.18%)	Nasdaq Futures 29,466.50 ▼ -103.50 (-0.35%)	Dow Futures 50,496.00 ▼ -46.00 (-0.09%)
10Y Treasury 4.59% ▲ +0.01%	US Dollar 99.35 ▲ +0.10 (+0.10%)	Bitcoin $77,216 ▼ -$327 (-0.42%)

Good morning! Friday, May 22, 2026, and futures are starting the session in the red across all three major indexes, though nothing that screams panic just yet. The real action this morning is in the headlines, not the futures tape, with a historic drug approval, a massive European takeover bid, and some pointed warnings about where this bull market might be heading. Pull up a chair, here is everything that matters before the bell.

👀 What to Watch Today

Friday sessions can be deceptively quiet, but today has a few things worth keeping your eyes on. Traders will be watching whether the modest futures losses deepen or recover as cash markets open, particularly in tech, where Nasdaq futures are leading the decline at -0.35%. Any fresh commentary on tariffs, Fed policy, or credit conditions could easily move the needle.

The mega-IPO conversation is a slow-burn theme that deserves attention today. With SpaceX, OpenAI, and Anthropic all reportedly eyeing public offerings before year-end, analysts are raising a flag that heavy IPO pipelines have historically coincided with late-stage bull markets. It is not a sell signal on its own, but it is the kind of narrative that shapes sentiment heading into the weekend.

Keep an eye on the 10-year Treasury yield sitting at 4.59% and the 30-year holding above 5.11%. Those levels continue to act as a quiet headwind for growth and rate-sensitive stocks. The dollar index ticking up to 99.35 also puts mild pressure on multinationals reporting in greenbacks.

How the Rich Retire [ad]

🌏 Overnight Recap

The big overnight headline belongs to Novo Nordisk (NVO). The European Medicines Agency issued a positive recommendation for Wegovy in pill form, clearing the path for it to become the first oral weight-loss drug available in Europe. That is a genuinely significant milestone. Up until now, GLP-1 treatments have required injections, and a pill format opens the door to a much broader patient base. Watch NVO closely at the open.

Over in Europe, private equity firm CVC Capital Partners and Belgian investment group GBL (GBL) launched a full voluntary cash offer worth 10.7 billion euros, roughly 12.43 billion dollars, to acquire Italian pharmaceutical company Recordati. The deal signals continued appetite for large-scale M&A in the European pharma space, even in a higher rate environment.

Hyundai (HYMLF) is also in the news for less welcome reasons. The automaker is recalling 421,078 U.S. vehicles after NHTSA flagged a brake software error that could cause brakes to engage unexpectedly. That kind of safety recall tends to generate headline risk more than lasting stock damage, but it is worth monitoring consumer sentiment around the brand.

Private interview with the most connected man in Washington [ad]

📊 Pre-Market Movers

Novo Nordisk (NVO) is the headline mover this morning after the European Medicines Agency recommended approval for an oral version of Wegovy. This is a landmark moment for the GLP-1 space, and the market is expected to respond accordingly. The oral format could dramatically expand the addressable patient population across Europe, which is a material revenue catalyst.

Estee Lauder (EL) is also flashing green in pre-market trading and earned a spot among the top gainers in the S&P 500. The beauty giant has had a rough stretch, so any meaningful bounce will attract attention from both momentum traders and value-focused investors watching for a longer-term turnaround signal.

Hyundai (HYMLF) faces some negative pre-market attention following the NHTSA recall announcement covering over 421,000 vehicles with a brake software defect. While recalls do not always translate into lasting stock pressure, the safety nature of this one and the sheer volume of affected vehicles could generate some selling interest early in the session.

SpaceX takes major step toward IPO [ad]

🔍 Today's Watchlist

1. NVO: Watch for a gap at the open after the European Wegovy pill approval recommendation
2. 10-Year yield at 4.59%: Any move toward 4.65% could pressure growth stocks into the close
3. EL: Estee Lauder shares are climbing pre-market, check for volume confirmation at the open
4. HYMLF: Hyundai recall headlines may weigh on sentiment, watch for any broader auto sector ripple
5. IPO pipeline chatter: SpaceX and OpenAI market-peak warnings could surface in analyst notes today

🎯 The Morning Playbook

The setup heading into Friday is a mild risk-off lean, not a dramatic one. Futures losses are modest, the dollar is nudging higher, and bond yields are holding at levels that have proven to be a persistent drag on valuations. The playbook here is to stay selective rather than reactive.

The Novo Nordisk story is genuinely worth digging into if you have exposure to health care or the broader GLP-1 theme. A pill-format approval in Europe is not just a headline, it is a potential market-expansion story with real revenue implications. Meanwhile, the mega-IPO warning from analysts around SpaceX and OpenAI is the kind of macro signal worth filing away, even if it does not require immediate action.

Heading into the weekend, the simplest discipline is to let the first hour of trading reveal the real direction before making any bold moves. Fridays have a way of sorting themselves out once the noise clears. Trade what you see, not what the futures told you at 7 a.m.

Rickards: A Change To My Gold Thesis? [ad]